Bone complications of androgen deprivation therapy: Screening, prevention, and treatment

Current Opinion in Urology

Volumn 20, Issue 3, 2010, Pages 247-252

  Lattouf, Jean Baptiste ^a   Saad, Fred ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Bisphosphonates; Denosumab; Osteopenia; Osteoporosis; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; FRACTURE; HUMAN; METASTASIS; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL; BONE DENSITY; DIPHOSPHONATES; HUMANS; MALE; MASS SCREENING; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 77951295023     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32833835be     Document Type: Review

References (42)

1. Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone releasing hormone agonists for prostate cancer. BJU Int 2000; 86:449-452.
2. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154-164. (Pubitemid 40096612)
3. Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003; 61:127-131.
4. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002; 60:79-85.
5. Saad F, Higano CS, Sartor O, et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006; 4:257-262. (Pubitemid 43779882)
6. Lattouf JB, Saad F. Preservation of bone health in prostate cancer. Curr Opin Support Palliat Care 2007; 1:192-197.
7. Oncken C, Prestwood K, Kleppinger A, et al. Impact of smoking cessation on bone mineral density in postmenopausal women. J Womens Health 2006; 15:1141-1150. (Pubitemid 46157486)
8. Tucker KL, Morita K, Qiao N, et al. Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: the Framingham Osteoporosis study. Am J Clin Nutr 2006; 84:936-942. (Pubitemid 44715678)
9. Prentice A. Diet, nutrition, and the prevention of osteoporosis. Public Health Nutr 2004; 7:227-243.
10. Saad F, Higano CS, Sartor O, et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006; 4:257-262. (Pubitemid 43779882)
11. Smith MR, McGovern FJ, Zietman AL. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2000; 345:948-955.
12. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003; 97:789-795. (Pubitemid 36125814)
13. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604-610. (Pubitemid 30659471)
14. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998; 4:1377-1382. (Pubitemid 28506801)
15. Diamond T, Campbell J, Bryant C, et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83:1561-1566. (Pubitemid 28465474)
16. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 354:948-955.
17. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21:4277-4284.
18. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346:653-661. (Pubitemid 34815869)
19. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001; 92:1444-1450. (Pubitemid 32947828)
20. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948-955.
21. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20 (Suppl 2): 45-54. (Pubitemid 35303443)
22. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
23. Saad F, Gleason DM, Murray R, et al., for the Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882. (Pubitemid 38807610)
24. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169:2008-2012. (Pubitemid 36576705)
25. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonistinduced bone loss in men with prostate cancer. J Clin Oncol 2007; 25:1038-1042. (Pubitemid 46596753)
26. Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol 2004; 45:26-34. (Pubitemid 37548989)
27. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases (cochrane review). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
28. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479-1491. (Pubitemid 351229318)
29. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9 (Suppl 4):28-37. (Pubitemid 39363166)
30. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-432.
31. Polascik TJ. Bone health in prostate cancer patients receiving androgendeprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis 2008; 11:13-19.
32. Steiner MS, Patterson A, Israeli R, et al. Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22 (Suppl):4597.
33. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008; 179:152- 155; Epub 2007 Nov 14. (Pubitemid 350216737)
34. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641-1647.
35. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282:637-645. (Pubitemid 29384151)
36. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin- releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89:3841-3846. (Pubitemid 39071482)
37. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007; 9 (Suppl1):S7.
38. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-831. (Pubitemid 43290920)
39. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765.
40. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26:4875-4882.
41. Smith MR, Egerdie B, Hernàndez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
42. Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 2002; 29 (6 Suppl 21):19-27. (Pubitemid 36222939)